Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Limited Stage Small Cell Lung Cancer 1Hepatic Encephalopathy 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × Glucose × Clear all
NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00753740 2020-06-12

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Lumos Pharma

Phase 2 Withdrawn
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡